Production (Stage)
Inozyme Pharma, Inc.
INZY
$3.98
-$0.01-0.25%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -28.04M | -27.07M | -24.57M | -27.03M | -23.35M |
| Total Depreciation and Amortization | 176.00K | 177.00K | 195.00K | 188.00K | 182.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.65M | 1.89M | 1.77M | 1.03M | -28.00K |
| Change in Net Operating Assets | -2.94M | 5.82M | -1.92M | 2.16M | -1.34M |
| Cash from Operations | -29.15M | -19.19M | -24.53M | -23.66M | -24.53M |
| Capital Expenditure | -- | -17.00K | -13.00K | 0.00 | -32.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 33.68M | 15.46M | 23.36M | 17.82M | 10.43M |
| Cash from Investing | 33.68M | 15.44M | 23.35M | 17.82M | 10.39M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 228.00K | 258.00K | 10.52M | 458.00K | 159.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 228.00K | 258.00K | 10.52M | 458.00K | 159.00K |
| Foreign Exchange rate Adjustments | 2.00K | -4.00K | -1.00K | -1.00K | 10.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 4.77M | -3.49M | 9.34M | -5.39M | -13.97M |